FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DUGGAN ROBERT W 		2. Issuer Name and Ticker or Trading Symbol

PHARMACYCLICS INC [ PCYC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chairman and CEO
(Last)          (First)          (Middle)

C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/26/2015
(Street)

SUNNYVALE, CA 94085
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/17/2015     G   V 152635   D $0.00   13230316   D    
Common Stock   3/18/2015     G   V 4785   D $0.00   13225531   (1) D   (1)  
Common Stock   5/26/2015     U    13225531   (1) D $261.25   (2) 0   D    
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (4)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (5)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (6)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (7)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (8)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (9)
Common Stock   5/26/2015     U    21908   D $261.25   (2) 0   I   By Trust   (3) (10)
Common Stock   5/26/2015     U    8404   D $261.25   (2) 0   I   By Child   (3)
Common Stock   5/26/2015     U    8404   D $261.25   (2) 0   I   By Child   (3)
Common Stock   5/26/2015     U    8404   D $261.25   (2) 0   I   By Child   (3)
Common Stock   5/26/2015     U    8404   D $261.25   (2) 0   I   By Child   (3)
Common Stock   5/26/2015     U    8404   D $261.25   (3) 0   I   By Child   (3)
Common Stock   5/26/2015     U    170379   D $261.25   (2) 0   I   Managed Accounts   (11)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Includes (i) 1,020,756 shares owned by Mr. Duggan's spouse; (ii) 5,421 shares owned by Blazon Corp. ("Blazon"), as the sole stockholder of Blazon, Mr. Duggan may be deemed to beneficially own the shares owned by Blazon; (iii) 283,784 shares owned by MultiAccess Computing Corp. ("MultiAccess"), as the sole stockholder of MultiAccess, Mr. Duggan may be deemed to beneficially own the shares owned by MultiAccess,; (iv) 161,760 shares held in irrevocable trusts for the benefit of Mr. Duggan's children (for which neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees) as additionally individually listed in the boxes below and as further described in footnotes 2 through 9; and (v) 42,020 shares directly owned by certain of Mr. Duggan's children as additionally individually listed in the boxes below. Mr. Duggan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
( 2)  Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
( 3)  Mr. Duggan disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
( 4)  Shares directly owned by David Michael Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the David Michael Duggan Trust.
( 5)  Shares directly owned by Daniel Douglas Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Daniel Douglas Duggan Trust.
( 6)  Shares directly owned by Dylan Duke Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Dylan Duke Duggan Trust.
( 7)  Shares directly owned by Diamond Augustus Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Diamond Augustus Duggan Trust.
( 8)  Shares directly owned by Dante Eon Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Dante Eon Duggan Trust.
( 9)  Shares directly owned by Dsara Ann Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Dsara Ann Duggan Trust.
( 10)  Shares directly owned by Diana Star Duggan Trust, an irrevocable trust. Neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees of the Diana Star Duggan Trust.
( 11)  Shares held in managed accounts pursuant to agreements with Robert W. Duggan & Associates ("RWD&A"), of which Robert W. Duggan is a principal. Mr. Duggan disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DUGGAN ROBERT W
C/O PHARMACYCLICS, INC.
995 EAST ARQUES AVENUE
SUNNYVALE, CA 94085 		X X Chairman and CEO

Signatures
/s/ Robert W. Duggan 5/27/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(MM) (NASDAQ:PCYC)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 (MM) 차트를 더 보려면 여기를 클릭.
(MM) (NASDAQ:PCYC)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 (MM) 차트를 더 보려면 여기를 클릭.